Sippican Capital Advisors Lowers Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Sippican Capital Advisors lessened its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 31.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 20,753 shares of the company’s stock after selling 9,560 shares during the quarter. Sippican Capital Advisors’ holdings in Apellis Pharmaceuticals were worth $662,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wolverine Asset Management LLC bought a new stake in Apellis Pharmaceuticals in the 3rd quarter worth approximately $27,000. True Wealth Design LLC bought a new stake in Apellis Pharmaceuticals during the third quarter worth approximately $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals in the 3rd quarter worth approximately $56,000. KBC Group NV increased its position in shares of Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the period. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $29.47 on Thursday. The business’s 50 day moving average price is $32.20 and its 200-day moving average price is $32.96. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm has a market capitalization of $3.67 billion, a PE ratio of -14.52 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue was up 78.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.17) EPS. As a group, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on APLS shares. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target for the company. in a research note on Tuesday, December 17th. Scotiabank dropped their price objective on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada restated a “sector perform” rating and set a $26.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday. Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Insider Transactions at Apellis Pharmaceuticals

In other news, insider Caroline Baumal sold 2,816 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $33.81, for a total value of $95,208.96. Following the transaction, the insider now directly owns 55,560 shares in the company, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $62,279.00. Following the completion of the sale, the chief financial officer now directly owns 88,100 shares of the company’s stock, valued at $2,528,470. The trade was a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 55,112 shares of company stock worth $1,655,767 in the last 90 days. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).